Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 5/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864950 | 0.81 | KIF11 (0.46) | KIF11SLC6A4SLC6A2 | |
| SCHEMBL9634657 | 0.80 | APOBEC3G (0.59) | APOBEC3GLDHASLC6A4FFAR4PDCD1 | |
| SCHEMBL6233930 | 0.80 | KIF11 (0.40) | APOBEC3GKIF11 | |
| SCHEMBL28802335 | 0.76 | APOBEC3G (0.59) | APOBEC3GSLC6A4FFAR4SLC6A2 | |
| SCHEMBL6238584 | 0.74 | ALDH1A1 (0.44) | APOBEC3GKIF11 | |
| SCHEMBL30821022 | 0.74 | KIF11 (0.38) | KIF11TSHR | |
| SCHEMBL7557262 | 0.73 | KIF11 (0.35) | APOBEC3GKIF11 | |
| SCHEMBL7262305 | 0.72 | APOBEC3G (1.00) | APOBEC3GLDHASLC6A4PDCD1CD274 | |
| SCHEMBL4442278 | 0.72 | APOBEC3G (0.73) | APOBEC3GLDHASLC6A4SLC6A2 | |
| SCHEMBL864337 | 0.71 | CASP3 (0.43) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398777-B1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMA SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| US-8450314-B2 | Pyrimidopyridazine derivatives useful as P38 MAPK inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-28 | — | — | US | disclosed |
| US-20120077809-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-03-29 | — | — | US | disclosed |
| EP-2398777-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094955-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077809-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | MAPK1, MAPK4, MAPK7 | APOBEC3G 3929/4885KIF11 1455/4885LDHA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.